Global DNA Damage Response Targeting Therapeutics Market Report 2021: Current Landscape and the Likely Adoption of DNA Damage Response Targeting Therapeutics in Healthcare Over the Next Decade Dublin, Oct. 06, 2021 (GLOBE NEWSWIRE) -- The "DNA Damage Response Targeting Therapeutics Market by Target Disease Indication, Therapeutic Area, Target Molecule, Type of Molecule, Route of...

The DNA damage response (DDR) targeting therapeutics market is projected to be worth USD 1.07 billion in 2030, growing at an annualized rate of 52.6% during the period 2024-2030, claims Roots Analysis London, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “DNA Damage Response Targeting Therapeutics (beyond PARP inhibitors) Market, 2021-2030” report to its list of...

ProLynx announces allowance of additional U.S. patent for PLX038, a novel DNA damage response enhancer SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Prolynx LLC (San Francisco, CA) announced it received a Notice of Allowance for its DNA damage enhancer PLX038 (PEG~SN-38), currently in Phase 1...